Discontinuation of Supportive Therapies in Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor

Recommended De-escalation Approach

• The American Thoracic Society recommends considering discontinuation of inhaled medications with insufficient evidence of benefit, such as inhaled anticholinergics and beta-adrenergic receptor agonists, as the first tier in a sequential de-escalation approach 1, 2
• The American Thoracic Society suggests considering discontinuation of medications with low certainty of benefit, such as leukotriene modifiers, N-acetylcysteine, and glutathione, as the second tier in a sequential de-escalation approach 2
• The American Thoracic Society recommends considering discontinuation of oral antistaphylococcal antibiotics if appropriate, as the third tier in a sequential de-escalation approach 3
• Patients with residual symptoms may benefit from continuing certain supportive therapies, according to the American Thoracic Society 4